“Patients with lung cancer (LC) are known to be at increased risk for venous thromboembolism (VTE). Venous thromboembolism is associated with increased risk for early mortality”
If you’ve been diagnosed with LC you’re probably feeling a host of negative emotions. And talking with your oncologist probably isn’t cheering you up. But there’s hope in the form of a LC two-fer. That’s right. One evidence-based, non-toxic therapy that can treat two challenges faced by LC patients.
As the first study linked and excerpted below explains, LC patients have an increased risk of Venous thromboembolism aka a blood clot. In fact, the increased risk of a blood clot comes with many different cancers.
A VTE is a common side effect. I developed two blood clots in the year following my cancer diagnosis and active treatment.
The solution? Supplementation with an evidence-based, non-toxic therapy that also kills lung cancer. According to the second study below, fish oil has anti-lung cancer action.
I have taken Life Extension Super Omega-3 Fatty Acids for years. Though there are many different brands of fish oil out there, I take this brand because it has been evaluated and approved by Consumerlab.com, it is inexpensive and most importantly, this formula includes heart healthy components such as olive extract.
I am both a cancer survivor and cancer coach. Have you been diagnosed with LC? If you would like to learn more about evidence-based, non-toxic lung cancer therapies please scroll down the page, post a question or comment and I will reply to you ASAP.
Learn More About Blood Clots aka Deep Vein Thromboses- click now
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
“Patients with LC are known to be at increased risk for venous thromboembolism (VTE). Venous thromboembolism is associated with increased risk for early mortality…
Of 1,980 patients with LC who were enrolled from 2011 to 2012, 84% had non‐small cell LC. During the first 6 months, 121 patients developed a VTE (6.1%), of which:
- 47% had pulmonary embolism,
- 46% deep vein thrombosis,
- 3% catheter‐associated thrombosis, and
- 4% visceral thrombosis.
Conclusion-In this global, prospective, real‐world analysis, several demographic, geographic, and clinical factors are independent risk factors for VTE and early mortality in patients with LC. The VTE‐RS represents a significant independent predictor of early mortality but not for VTE in lung cancer in the era of targeted therapy…”
“Taken as a whole, these data suggest that fish oil derived n-3 fatty acid EPA exerts a relatively stronger anti-proliferative activity in COX-2 expressing Non Small Cell Lung Cancer A549 cells…”
APPIP ERROR: amazonproducts[
AccessDeniedAwsUsers|The Access Key Id AKIAJAJ37JVNL7OUU4CA is not enabled for accessing this version of Product Advertising API. Please migrate your credentials as referred here https://webservices.amazon.com/paapi5/documentation/migrating-your-product-advertising-api-account-from-your-aws-account.html.
[…] Lung Cancer Patients at Risk for VTE and Early Mortality- […]Reply